PepGen, Inc. (NASDAQ:PEPG) Receives Average Rating of “Moderate Buy” from Analysts

PepGen, Inc. (NASDAQ:PEPG) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.60.

Several research firms have weighed in on PEPG. HC Wainwright upped their price objective on shares of PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Guggenheim increased their price objective on PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Oppenheimer initiated coverage on PepGen in a research note on Wednesday. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a research report on Thursday, January 22nd.

PepGen Price Performance

Shares of PEPG opened at $6.24 on Friday. The business’s 50-day moving average is $5.84 and its 200-day moving average is $4.52. The company has a market capitalization of $429 million, a price-to-earnings ratio of -2.21 and a beta of 1.91. PepGen has a fifty-two week low of $0.88 and a fifty-two week high of $7.80.

Institutional Trading of PepGen

A number of institutional investors have recently added to or reduced their stakes in PEPG. RA Capital Management L.P. increased its stake in shares of PepGen by 87.7% during the 3rd quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock worth $92,698,000 after purchasing an additional 9,375,000 shares during the last quarter. Commodore Capital LP acquired a new stake in shares of PepGen in the 3rd quarter valued at $10,891,000. Vivo Capital LLC bought a new stake in PepGen in the third quarter worth $10,742,000. Viking Global Investors LP increased its position in PepGen by 134.9% during the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock worth $16,089,000 after buying an additional 2,000,000 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in PepGen during the fourth quarter valued at about $10,072,000. 58.01% of the stock is currently owned by institutional investors and hedge funds.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).